Insider · CIK 0001920738

Bizily Scott

Reports to the SEC for 1 company · EMERYVILLE, CA

sec.gov

Transactions

Companies

Filings

CIK

0001920738

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-09-16	FDMT4D Molecular Therapeutics, Inc.M Exercise/Conversion	Chief Legal Officer	MExercise/Conversion	+1,635 sh	$4.14	+$6,768.9	10,252
2026-09-16	FDMT4D Molecular Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Legal Officer	MExercise/Conversion	−1,635 sh	—	—	58,066
2026-09-16	FDMT4D Molecular Therapeutics, Inc.S Sale	Chief Legal Officer	SSale	−1,635 sh	$13.65	−$22.3K	8,617
2026-09-01	FDMT4D Molecular Therapeutics, Inc.M Exercise/Conversion	Chief Legal Officer	MExercise/Conversion	+584 sh	$6.49	+$3,790.16	9,201
2026-09-01	FDMT4D Molecular Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Legal Officer	MExercise/Conversion	−584 sh	—	—	2,959
2026-09-01	FDMT4D Molecular Therapeutics, Inc.S Sale	Chief Legal Officer	SSale	−584 sh	$14.00	−$8,176	8,617
2026-08-17	FDMT4D Molecular Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Legal Officer	MExercise/Conversion	−1,635 sh	—	—	59,701
2026-08-17	FDMT4D Molecular Therapeutics, Inc.M Exercise/Conversion	Chief Legal Officer	MExercise/Conversion	+1,635 sh	$4.14	+$6,768.9	10,252
2026-08-17	FDMT4D Molecular Therapeutics, Inc.S Sale	Chief Legal Officer	SSale	−1,635 sh	$12.20	−$19.9K	8,617
2026-08-13	FDMT4D Molecular Therapeutics, Inc.S Sale	Chief Legal Officer	SSale	−1,635 sh	$12.00	−$19.6K	8,617
2026-08-13	FDMT4D Molecular Therapeutics, Inc.M Exercise/Conversion	Chief Legal Officer	MExercise/Conversion	+1,635 sh	$4.14	+$6,768.9	10,252
2026-08-13	FDMT4D Molecular Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Legal Officer	MExercise/Conversion	−1,635 sh	—	—	61,336
2026-06-30	FDMT4D Molecular Therapeutics, Inc.M Exercise/Conversion	Chief Legal Officer	MExercise/Conversion	+5,752 sh	$6.49	+$37.3K	15,183
2026-06-30	FDMT4D Molecular Therapeutics, Inc.M Exercise/Conversion	Chief Legal Officer	MExercise/Conversion	+814 sh	$4.14	+$3,369.96	9,431
2026-06-30	FDMT4D Molecular Therapeutics, Inc.S Sale	Chief Legal Officer	SSale	−6,566 sh	$14.00	−$91.9K	8,617
2026-06-30	FDMT4D Molecular Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Legal Officer	MExercise/Conversion	−5,752 sh	—	—	3,543
2026-06-30	FDMT4D Molecular Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Legal Officer	MExercise/Conversion	−814 sh	—	—	62,971
2026-06-23	FDMT4D Molecular Therapeutics, Inc.S Sale	Chief Legal Officer	SSale	−9,810 sh	$12.00	−$118K	8,617
2026-06-23	FDMT4D Molecular Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Legal Officer	MExercise/Conversion	−9,810 sh	—	—	63,785
2026-06-23	FDMT4D Molecular Therapeutics, Inc.M Exercise/Conversion	Chief Legal Officer	MExercise/Conversion	+9,810 sh	$4.14	+$40.6K	18,427
2026-03-25	FDMT4D Molecular Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Legal Officer	AAward	+217K sh	—	—	217,000
2025-12-16	FDMT4D Molecular Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Legal Officer	MExercise/Conversion	−1,635 sh	—	—	73,595
2025-12-16	FDMT4D Molecular Therapeutics, Inc.S Sale	Chief Legal Officer	SSale	−1,635 sh	$10.90	−$17.8K	3,594
2025-12-16	FDMT4D Molecular Therapeutics, Inc.M Exercise/Conversion	Chief Legal Officer	MExercise/Conversion	+1,635 sh	$4.14	+$6,768.9	5,229
2025-11-17	FDMT4D Molecular Therapeutics, Inc.S Sale	Chief Legal Officer	SSale	−1,635 sh	$10.59	−$17.3K	3,594
2025-11-17	FDMT4D Molecular Therapeutics, Inc.M Exercise/Conversion	Chief Legal Officer	MExercise/Conversion	+1,635 sh	$4.14	+$6,768.9	5,229
2025-11-17	FDMT4D Molecular Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Legal Officer	MExercise/Conversion	−1,635 sh	—	—	75,230
2025-10-24	FDMT4D Molecular Therapeutics, Inc.M Exercise/Conversion	Chief Legal Officer	MExercise/Conversion	+1,084 sh	$6.49	+$7,035.16	6,272
2025-10-24	FDMT4D Molecular Therapeutics, Inc.S Sale	Chief Legal Officer	SSale	−2,678 sh	$12.00	−$32.1K	3,594
2025-10-24	FDMT4D Molecular Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Legal Officer	MExercise/Conversion	−1,084 sh	—	—	9,295
2025-10-16	FDMT4D Molecular Therapeutics, Inc.S Sale	Chief Legal Officer	SSale	−1,635 sh	$10.17	−$16.6K	5,188
2025-10-16	FDMT4D Molecular Therapeutics, Inc.M Exercise/Conversion	Chief Legal Officer	MExercise/Conversion	+1,635 sh	$4.14	+$6,768.9	6,823
2025-10-16	FDMT4D Molecular Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Legal Officer	MExercise/Conversion	−1,635 sh	—	—	76,865
2025-10-09	FDMT4D Molecular Therapeutics, Inc.S Sale	Chief Legal Officer	SSale	−2,408 sh	$10.00	−$24.1K	5,188
2025-09-23	FDMT4D Molecular Therapeutics, Inc.S Sale	Chief Legal Officer	SSale	−2,407 sh	$8.00	−$19.3K	7,596
2025-03-06	FDMT4D Molecular Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Legal Officer	AAward	+78.5K sh	—	—	78,500
2024-09-16	FDMT4D Molecular Therapeutics, Inc.M Exercise/Conversion	Chief Legal Officer	MExercise/Conversion	+500 sh	$6.49	+$3,245	7,281
2024-09-16	FDMT4D Molecular Therapeutics, Inc.S Sale	Chief Legal Officer	SSale	−500 sh	$16.33	−$8,165	6,781
2024-09-16	FDMT4D Molecular Therapeutics, Inc. · Stock Option (Right To Buy)M Exercise/Conversion	Chief Legal Officer	MExercise/Conversion	−500 sh	—	—	10,379
2024-08-19	FDMT4D Molecular Therapeutics, Inc. · Stock Option (Right To Buy)M Exercise/Conversion	Chief Legal Officer	MExercise/Conversion	−500 sh	—	—	10,879
2024-08-19	FDMT4D Molecular Therapeutics, Inc.S Sale	Chief Legal Officer	SSale	−500 sh	$15.00	−$7,500	6,781
2024-08-19	FDMT4D Molecular Therapeutics, Inc.M Exercise/Conversion	Chief Legal Officer	MExercise/Conversion	+500 sh	$6.49	+$3,245	7,281
2024-07-16	FDMT4D Molecular Therapeutics, Inc. · Stock Option (Right To Buy)M Exercise/Conversion	Chief Legal Officer	MExercise/Conversion	−1,250 sh	—	—	32,502
2024-07-16	FDMT4D Molecular Therapeutics, Inc. · Stock Option (Right To Buy)M Exercise/Conversion	Chief Legal Officer	MExercise/Conversion	−500 sh	—	—	11,379
2024-07-16	FDMT4D Molecular Therapeutics, Inc.S Sale	Chief Legal Officer	SSale	−1,750 sh	$27.11	−$47.4K	6,781
2024-07-16	FDMT4D Molecular Therapeutics, Inc.M Exercise/Conversion	Chief Legal Officer	MExercise/Conversion	+1,250 sh	$8.04	+$10K	8,531
2024-07-16	FDMT4D Molecular Therapeutics, Inc.M Exercise/Conversion	Chief Legal Officer	MExercise/Conversion	+500 sh	$6.49	+$3,245	7,281
2024-07-11	FDMT4D Molecular Therapeutics, Inc. · Stock Option (Right To Buy)M Exercise/Conversion	Chief Legal Officer	MExercise/Conversion	−1,996 sh	—	—	23,004
2024-07-11	FDMT4D Molecular Therapeutics, Inc.M Exercise/Conversion	Chief Legal Officer	MExercise/Conversion	+1,996 sh	$15.78	+$31.5K	8,777
2024-07-11	FDMT4D Molecular Therapeutics, Inc.S Sale	Chief Legal Officer	SSale	−1,996 sh	$25.00	−$49.9K	6,781

Recent filings

Accepted (ET)
Sep 224
Bizily Scott0001193125-26-398204
SEC(opens sec.gov)
Sep 34
Bizily Scott0001193125-26-382245
SEC(opens sec.gov)
Aug 174
Bizily Scott0001193125-26-354313
SEC(opens sec.gov)
Jul 24
Bizily Scott0001920738-26-000004
SEC(opens sec.gov)
Jun 254
Bizily Scott0001920738-26-000002
SEC(opens sec.gov)

Companies

4D Molecular Therapeutics, Inc.Chief Legal OfficerFDMT

Address

C/O 4D MOLECULAR THERAPEUTICS, INC. 5858 HORTON STREET #455

EMERYVILLE, CA, 94608